“Based on pharmacokinetic studies, no dosage adjustment of REXULTI is required when administered
concomitantly with CYP2B6 inhibitors (e.g., ticlopidine) or gastric pH modifiers (e.g., omeprazole). Additionally,
no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6
(e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered
concomitantly with REXULTI.” (opens the source at this quote in a new tab)